Finance

Lists
SNYNF:OTCMKTS
Sanofi SA
78,55 US$
0,00%
(0,00) 1D
15 ოქტ, 12:34:26 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SNYNF...
Mkt. cap
98,92 მლრდ.
Avg. vol.
5,39 ათ.
Volume
117,00
52-wk high
106,34 US$
52-wk low
76,76 US$
Beta
0,32
Shares outstanding
1,21 მლრდ.
No. of employees
75 ათ.
Mkt. cap
98,92 მლრდ.
Avg. vol.
5,39 ათ.
Volume
117,00
52-wk high
106,34 US$
52-wk low
76,76 US$
Beta
0,32
Shares outstanding
1,21 მლრდ.
No. of employees
75 ათ.
News stories
From web sources and news partners
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000. Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOპოლ ჰადსონ | ბელენ გარიო
Employees74,8 ათ.
Founded1973
Headquartersპარიზი, ილ-დე-ფრანსი, საფრანგეთი
SectorPharmaceutical industry
Websitesanofi.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
13,17 მლრდ.
12,20 მლრდ.
11,24 მლრდ.
12,30 მლრდ.
Cost of goods sold
3,41 მლრდ.
3,63 მლრდ.
3,06 მლრდ.
2,89 მლრდ.
Cost of revenue
3,41 მლრდ.
3,63 მლრდ.
3,06 მლრდ.
2,89 მლრდ.
Research and development expenses
1,83 მლრდ.
2,29 მლრდ.
1,75 მლრდ.
2,23 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,29 მლრდ.
2,82 მლრდ.
2,33 მლრდ.
2,49 მლრდ.
Operating expense
5,97 მლრდ.
6,84 მლრდ.
5,94 მლრდ.
6,82 მლრდ.
Total operating expenses
9,39 მლრდ.
10,46 მლრდ.
9,00 მლრდ.
9,71 მლრდ.
Operating income
3,78 მლრდ.
1,74 მლრდ.
2,25 მლრდ.
2,59 მლრდ.
Other non operating income
-
122,00 მლნ.
-40,00 მლნ.
-91,00 მლნ.
EBT including unusual items
3,51 მლრდ.
-1,16 მლრდ.
2,01 მლრდ.
828,00 მლნ.
EBT excluding unusual items
3,67 მლრდ.
1,70 მლრდ.
2,14 მლრდ.
2,40 მლრდ.
Income tax expense
680,00 მლნ.
-348,00 მლნ.
420,00 მლნ.
451,00 მლნ.
Effective tax rate
19,38%
30,13%
20,85%
54,47%
Other operating expenses
1,39 მლრდ.
1,19 მლრდ.
1,33 მლრდ.
1,55 მლრდ.
Net income
2,80 მლრდ.
-801,00 მლნ.
1,61 მლრდ.
343,00 მლნ.
Net profit margin
21,28%
-6,56%
14,35%
2,79%
Earnings per share
-
1,53
1,88
-
Interest and investment income
114,00 მლნ.
79,00 მლნ.
60,00 მლნ.
64,00 მლნ.
Interest expense
-227,00 მლნ.
-
-138,00 მლნ.
-153,00 მლნ.
Net interest expenses
-113,00 მლნ.
79,00 მლნ.
-78,00 მლნ.
-89,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
4,20 მლრდ.
3,49 მლრდ.
2,78 მლრდ.
3,83 მლრდ.
Gain or loss from assets sale
266,00 მლნ.
-79,00 მლნ.
-
-9,00 მლნ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები